info@marketlookconsulting.com +1 347 441 0939

Global Biosimilars Market Report, Industry Analysis and Forecast to 2029

Request for Sample
  1. Home
  2. Healthcare
  3. Biosimilars Market

Biosimilars Market Report- Global Strategic Analysis, Size, Share, Trend, and Forecast (2022-2029)

Social Share Button
Healthcare

The Global Biosimilars market was valued at USD 19 billion in 2021 and is projected to reach USD 42.4 billion in 2029, at a Compound Annual Growth (CAGR) of 21% during the forecast period 2022-2029.

The pandemic had a positive effect on the helathcare sector as well. Globally, there was an extraordinary demand for certain medications for the urgent treatment of severe COVID-19 cases, which prompted calls for the quick approval of biosimilar versions of these medications. Europe and North America has always been the centre of attraction for medical assistance which is expected to project growth in the global Biosimilars market in the upcoming years. With attractive R&D facilities and inorganic growth strategies, companies are bolstering their growth and expansion across the world.

Global Biosimilars Market Overview

The global Biosimilars demand is dependent on the growth of cost effectiveness, quality of life, greater demand for technological advancement and some more factors. Diversification and the type of R&D done by major companies to manufacture better and affordable Biosimilars products is one of the keys to the growth of this industry. Additionally, the patents registered and the type of investment done on the trials is immense which is contributing hugely towards human wellbeing and the times to come.

Biosimilars Market Report Outlook

The Biosimilars market report focuses on different aspects regarding the phase of Biosimilars, and the different trends of that Biosimilars Market. The research analyses the different designs, and services types of the product to obtain a better understanding of the growth and trends of the market since 2019 which also facilitates the estimation of the upcoming growth of the market in the next 7 years.

Biosimilars Market Competitive Landscape

The Biosimilars Market report also holds competitive analysis which can be used to differentiate different designs of trials; technologies used in conducting the trials; prices; innovation in R&D; patents; organic and inorganic growth strategies; financial analysis to determine the revenue generation and other key aspects of the finance; new partnership, joint ventures, collaborations, and acquisitions; market share of the top competitors in the market; and understand the growth strategies being undertaken by these major players to analyse the future market trends.

Biosimilars Market Regional Analysis

The market synopsis will also cover the regional dynamics and growth prospects which would include regions- North America, Asia Pacific, Europe, Latin America, Middle East, and Africa. These regions will be analysed per country based on market drivers, restraints, opportunities, and trends to get a closer view of the market studied.

Moreover, the introduction of AI in the healthcare sector is driving the agility of medical management and focusing more on the patient experience, which in turn escalates the demand for better medical facilities across the developed countries in the world. Scrutinizing these factors for the countries is expected to enhance the value chain of the Biosimilars market and aid us with better insights about the same.

Biosimilars Market In-depth Analysis Aspects

Mention certain other aspects which will include the Porter Five Forces, Patent analysis, PESTEL Analysis, Export-Import data, and Industry Value Chain will also bind the analysis of the Biosimilars Market report.

Research Methodology

The study period of the market is considered to be 10 years (2019-2029) which will be analysed through the two major research techniques – Primary and Secondary Research methods. The primary research method includes the interviews of the key personnel in the industry considered as the industry experts, major distributors, suppliers, and consumer base sample survey to understand the direct perspective of the market. Additionally, these data are backed by the secondary research method which includes company overview through websites, annual reports, SEC filings, investor presentations, news, and databases. The growth trends are always measured based on current and past scenarios considering any recent news which can drastically impact the growth rate of the market studied. Moreover, the consumption forecast depends on the company’s upcoming plans and revenue generation aspects.

Benefits of The Report

  • The Biosimilars Market report is designed to understand the past, present, and future market scenarios considering all the growth, restraining, and other factors influencing the market studied.
  • The report is designed with the assistance of the industry experts for a better understanding of the market studied
  • The market is analysed with an in-depth study of the company’s view on the market considering the present economic, political, social, geographical, and legal factors.
  • To gain a clear insight for a better future perspective of the market studied in 360-degree synopsis.
  • Understand the competition in the market is a part of the market or a new entrant in the market.
  • Analyse the different aspects in different geographies influencing the growth of the Biosimilars Market through a diverse consumer base.

Table of Content

1. Market Overview

          1.1 Research Methodology

          1.2 Definitions and Scope

2. Market - Executive Summary

          2.1 Market Opportunity

          2.2 Key Trends by Product Segments

          2.3 Key Trends by Geography

3. Biosimilars Market Landscape

          3.1 Comparative analysis

                    3.1.1 Product Benchmarking - Top 10 companies

                    3.1.2 Top 5 Financials Analysis

                    3.1.3 Market Value split by Top 10 companies

                    3.1.4 Pricing Analysis

4. Market Forces

          4.1 Market Drivers

                    4.1.1 High Prevalence of Diseases

                    4.1.2 Technological Advancements

          4.2 Market Constraints

                    4.2.1 Changing Government Regulations

                    4.2.2 Other Constraints

          4.3 Market Challenges

          4.4 Porter’s Five Forces

                    4.4.1 Bargaining Power of Suppliers

                    4.4.2 Bargaining Power of Consumers

                    4.4.3 Threat of New Entrants

                    4.4.4 Threat of Substitute Products and Services

                    4.4.5 Degree of Competition

5. Biosimilars Market - Strategic Analysis

          5.1 Value Chain

          5.2 Opportunity

          5.3 Patent Analysis

6. Global Biosimilars Market Outlook

          6.1 Global Biosimilars Market Outlook, by Product, 2019-2029

                    6.1.1 Recombinant Glycosylated Proteins

                              6.1.1.1 Dental Lasers

                              6.1.1.2 Monoclonal Antibodies

                              6.1.1.3 Laboratory Machines

                    6.1.2 Recombinant Non-glycosylated Proteins

                              6.1.2.1 Insulin

                              6.1.2.2 Granulocyte Colony Stimulating Factor

                              6.1.2.3 Recombinant Human Growth Factor

                              6.1.2.4 Interferons

                    6.1.3 Recombinant Peptides

          6.2 Global Biosimilars Market Outlook, by Indication, 2019-2029

                    6.2.1 Chronic Diseases

                    6.2.2 Oncology

                    6.2.3 Autoimmune Diseases

                    6.2.4 Infectious Diseases

                    6.2.5 Blood Disorders

                    6.2.6 Growth Hormone Deficiency

                    6.2.7 Others

          6.3 Global Biosimilars Market Outlook, by Region, 2019-2029

7. Asia Pacific Biosimilars Market Outlook

          7.1 Key Snapshot

          7.2 Asia Pacific Biosimilars Market Outlook, by Product, 2019-2029

                    7.2.1 Recombinant Glycosylated Proteins

                              7.2.1.1 Dental Lasers

                              7.2.1.2 Monoclonal Antibodies

                              7.2.1.3 Laboratory Machines

                    7.2.2 Recombinant Non-glycosylated Proteins

                              7.2.2.1 Insulin

                              7.2.2.2 Granulocyte Colony Stimulating Factor

                              7.2.2.3 Recombinant Human Growth Factor

                              7.2.2.4 Interferons

                    7.2.3 Recombinant Peptidesz

          7.3 Asia Pacific Biosimilars Market Outlook, by Indication, 2019-2029

                    7.3.1 Chronic Diseases

                    7.3.2 Oncology

                    7.3 3 Autoimmune Diseases

                    7.3.4 Infectious Diseases

                    7.3.5 Blood Disorders

                    7.3.6 Growth Hormone Deficiency

                    7.3.7 Others

          7.4 Asia Pacific Biosimilars Market Outlook, by Country, 2019-2029

                    7.4.1 China Biosimilars Market Outlook, 2019-2029

                    7.4.2 India Biosimilars Market Outlook, 2019-2029

                    7.4.3 Japan Biosimilars Market Outlook, 2019-2029

                    7.4.4 South Korea Biosimilars Market Outlook, 2019-2029

                    7.4.5 Australia Biosimilars Market Outlook, 2019-2029

                    7.4.6 Rest of Asia Pacific Biosimilars Market Outlook, 2019-2029

8. North America Biosimilars Market Outlook

          8.1 Key Snapshot

          8.2 North America Biosimilars Market Outlook, by Product, 2019-2029

                    8.2.1 Recombinant Glycosylated Proteins

                              8.2.1.1 Dental Lasers

                              8.2.1.2 Monoclonal Antibodies

                              8.2.1.3 Laboratory Machines

                    8.2.2 Recombinant Non-glycosylated Proteins

                              8.2.2.1 Insulin

                              8.2.2.2 Granulocyte Colony Stimulating Factor

                              8.2.2.3 Recombinant Human Growth Factor

                              8.2.2.4 Interferons

                    8.2.3 Recombinant Peptidesz

          8.3 North America Biosimilars Market Outlook, by Indication, 2019-2029

                    8.3.1 Chronic Diseases

                    8.3.2 Oncology

                    8.3 3 Autoimmune Diseases

                    8.3.4 Infectious Diseases

                    8.3.5 Blood Disorders

                    8.3.6 Growth Hormone Deficiency

                    8.3.7 Others

          8.4 North America Biosimilars Market Outlook, by Country, 2019-2029

                    8.4.1 United States Biosimilars Market Outlook, 2019-2029

                    8.4.2 Canada Biosimilars Market Outlook, 2019-2029

                    8.4.3 Mexico Biosimilars Market Outlook, 2019-2029

9. Europe Biosimilars Market Outlook

          9.1 Key Snapshot

          9.2 Europe Biosimilars Market Outlook, by Product, 2019-2029

                    9.2.1 Recombinant Glycosylated Proteins

                              9.2.1.1 Dental Lasers

                              9.2.1.2 Monoclonal Antibodies

                              9.2.1.3 Laboratory Machines

                    9.2.2 Recombinant Non-glycosylated Proteins

                              9.2.2.1 Insulin

                              9.2.2.2 Granulocyte Colony Stimulating Factor

                              9.2.2.3 Recombinant Human Growth Factor

                              9.2.2.4 Interferons

                    9.2.3 Recombinant Peptidesz

          9.3 Europe Biosimilars Market Outlook, by Indication, 2019-2029

                    9.3.1 Chronic Diseases

                    9.3.2 Oncology

                    9.3 3 Autoimmune Diseases

                    9.3.4 Infectious Diseases

                    9.3.5 Blood Disorders

                    9.3.6 Growth Hormone Deficiency

                    9.3.7 Others

          9.4 Europe Biosimilars Market Outlook, by Country, 2019-2029

                    9.4.1 United Kingdom Biosimilars Market Outlook, 2019-2029

                    9.4.2 Germany Biosimilars Market Outlook, 2019-2029

                    9.4.3 France Biosimilars Market Outlook, 2019-2029

                    9.4.4 Italy Biosimilars Market Outlook, 2019-2029

                    9.4.5 Russia Biosimilars Market Outlook, 2019-2029

                    9.4.6 Rest of Europe Biosimilars Market Outlook, 2019-2029

10. Latin America Biosimilars Market Outlook

          10.1 Key Snapshot

          10.2 Latin America Biosimilars Market Outlook, by Product, 2019-2029

                    10.2.1 Recombinant Glycosylated Proteins

                              10.2.1.1 Dental Lasers

                              10.2.1.2 Monoclonal Antibodies

                              10.2.1.3 Laboratory Machines

                              10.2.2 Recombinant Non-glycosylated Proteins

                              10.2.2.1 Insulin

                              10.2.2.2 Granulocyte Colony Stimulating Factor

                              10.2.2.3 Recombinant Human Growth Factor

                              10.2.2.4 Interferons

                    10.2.3 Recombinant Peptidesz

          10.3 Latin America Biosimilars Market Outlook, by Indication, 2019-2029

                    10.3.1 Chronic Diseases

                    10.3.2 Oncology

                    10.3 3 Autoimmune Diseases

                    10.3.4 Infectious Diseases

                    10.3.5 Blood Disorders

                    10.3.6 Growth Hormone Deficiency

                    10.3.7 Others

          10.4 Latin America Biosimilars Market Outlook, by Country, 2019-2029

                    10.4.1 Brazil Biosimilars Market Outlook, 2019-2029

                    10.4.2 Argentina Biosimilars Market Outlook, 2019-2029

                    10.4.3 Rest of Latin America Biosimilars Market Outlook, 2019-2029

11. Middle East and Africa Biosimilars Market Outlook

          11.1 Key Snapshot

          11.2 Middle East and Africa Biosimilars Market Outlook, by Product, 2019-2029

                    11.2.1 Recombinant Glycosylated Proteins

                              11.2.1.1 Dental Lasers

                              11.2.1.2 Monoclonal Antibodies

                              11.2.1.3 Laboratory Machines

                    11.2.2 Recombinant Non-glycosylated Proteins

                              11.2.2.1 Insulin

                              11.2.2.2 Granulocyte Colony Stimulating Factor

                              11.2.2.3 Recombinant Human Growth Factor

                              11.2.2.4 Interferons

                    10.2.3 Recombinant Peptidesz

          11.3 Middle East and Africa Biosimilars Market Outlook, by Indication, 2019-2029

                    11.3.1 Chronic Diseases

                    11.3.2 Oncology

                    11.3 3 Autoimmune Diseases

                    11.3.4 Infectious Diseases

                    11.3.5 Blood Disorders

                    11.3.6 Growth Hormone Deficiency

                    11.3.7 Others

          11.4 Middle East and Africa Biosimilars Market Outlook, by Country, 2019-2029

                    11.4.1 Saudi Arabia Biosimilars Market Outlook, 2019-2029

                    11.4.2 UAE Biosimilars Market Outlook, 2019-2029

                    11.4.3 South Africa Biosimilars Market Outlook, 2019-2029

                    11.4.4 Rest of Middle East and Africa Biosimilars Market Outlook, 2019-2029

12. Biosimilars Market -Entropy

          12.1 New Product Launches

          12.2 M&A, Collaborations, JVs, and Partnerships

13. Biosimilars Market Company Analysis

          13.1 Market Share Analysis, Financial Analysis, Product Synopsis, Recent News, and Developments

          13.2 Pfizer, Inc.

          13.3 Intas Pharmaceuticals Ltd.

          13.4 Biocon

          13.5 Dr. Reddy’s Laboratories Ltd.

          13.6 Teva Pharmaceutical Industries Ltd.

          13.7 Sandoz International GmbH (A Novartis Division)

          13.8 Celltrion Inc.

          13.9 Amgen, Inc.

          13.10 STADA Arzneimittel AG

          13.11 Apotex Inc.

Top Major Players List :-Biosimilars Market

  • Pfizer, Inc.
  • Intas Pharmaceuticals Ltd.
  • Biocon
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (A Novartis Division)
  • Celltrion Inc.
  • Amgen, Inc.
  • STADA Arzneimittel AG
  • Apotex Inc.

SELECT LICENCE TYPE

  • Single User Licence     $2950
  • Multi User Licence     $4950
  • Enterprice User Licence     $6950


Related Reports